Humoral immune responses after receiving COVID-19 vaccination in cirrhotic patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210622002

Enrollment

100

Registered

2021-06-22

Start date

2021-06-21

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis vaccination COVID-19 cirrhosis, vaccination, COVID-19, CoronaVac, AstraZeneca, SARS-CoV-2 vaccine.

Interventions

The healthy volunteer who have planned to receive the COVID-19 vaccine.,Cirrhotic patients who have planned to receive COVID-19 vaccine. Liver cirrhosis is defined by the evidence of 1) imaging either

Prevention,Prevention

Healty volunteer,Cirrhosis

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18 years old 2. Patients with the diagnosis of liver cirrhosis. 3. Plan to receive a COVID-19 vaccine.

Exclusion criteria

Exclusion criteria: 1. Inability to provide informed consent. 2. Pregnancy 3. Receiving immunosuppressive drugs including prednisolone >15 mg/day 4. Immune deficiency including congenital or acquired immune deficiency 5. Known vaccine allergy 6. Not receiving a complete course of vaccination or receiving a different type of vaccine 7. Receiving other vaccines during COVID-19 vaccination

Design outcomes

Primary

Measure	Time frame
humoral response (SARS CoV-2 antibody level) after complete vaccination in cirrhotic patients Before compared with after vaccination Mean (SD), percentage	—

Secondary

Measure	Time frame
Side effects after vaccination after vaccination percentage	—

Countries

Thailand

Contacts

Public ContactApichat Kaewdech

Prince of Songkla University

apichat.ka@psu.ac.th66828013379

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026